Minocycline decreases blood glucose and triglyceride levels and reverses histol ogical and immunohisto- chemical alterations in pancreas, liver and kidney of alloxan-induced diabetic rats

• Autor(a) principal: Viana, Glauce S. Barros
• Data de Publicação: 2014
• Outros Autores: Pessoa, Igor X., Ferreira, Pollyana L. Tavares, Carvalho, Antônio Germano G., Garcia, Francisca Adilfa O., Menezes, Silvana M. Siqueira, Neves, Kelly Rose Tavares, Alves, Ana Paula Negreiros Nunes, Cerqueira, Gilberto Santos, Brito, Gerly Anne C.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da Universidade Federal do Ceará (UFC)
• Texto Completo: http://www.repositorio.ufc.br/handle/riufc/10271
• topic: Minociclina; Diabetes Mellitus; Hiperglicemia; Hipertrigliceridemia

Increasing evidence suggests that oxidative stress and inflammation play major roles in diabetes mellitus and its complications. Furthermore, hyperg lycemia increases the produc tion of free radicals, resulting in oxidative stress. Minocycline presents potent anti-inflammatory and antioxidant activities, as evaluated by in vivo and in vitro models. In the present study, the minocycline anti-diabetic effect was assessed in the model of alloxan-induced diabetes. Alloxan was injected to male Wistar rats (50 mg/kg, intravenously), and their blood was collected 48 h later and also after treatments, for measurements of glycemia, triglycerides, cholesterol and liver transaminases. Groups of untreated diabetic controls and diabetic treated with minoc ycline (1 to 50 mg/kg, peritoneally, p.o.) or glibenclamide (5 mg/kg, p.o., as reference), for different periods, were used. Furthermore, slices of pancreas, liver and kidney were submitted to hi stological and immunohistochemical analyses. While significant decreases in glucose and triglycerides were shown at the 5th and mainly at the 30th days after minocycline treatments, as compared to the untreated diabetic group, no changes were observed in total cholesterol, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels. Histological analyses of pancreas, liver and kidney showed that minocycline significantly reversed tissue alterations, as those seen in untreated diab etic animals. Besides, minocycline also reduced tumor necrosis factor (TNF)-alpha, cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) expressions. The beneficial minocycline effects in diabet es could be due, at least partly, to its anti- inflammatory and antioxidant properties, indicating that this drug may be a therapeutic alternative in diabetes mellitus and other pathological condition s where inflammation plays a significant role.